CorMedix Soars 11.32% on DefenCath Implementation

CorMedix's stock surged 11.32% in pre-market trading on June 23, 2025, driven by significant developments in its customer implementation strategy.

CorMedix has announced that its LDO customer has started ordering and will begin implementing DefenCath in its patients. This implementation is set to initially target at least 50% of the customer's patient base, marking a substantial step forward in the adoption of DefenCath.

This news follows CorMedix's expansion of its dialysis customer implementation, further solidifying its position in the market. The company's strategic moves are expected to enhance its market presence and drive future growth.